{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:54:13Z","timestamp":1767113653485,"version":"3.48.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2024\/02796-1"],"award-info":[{"award-number":["2024\/02796-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2023\/08735-1"],"award-info":[{"award-number":["2023\/08735-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s44313-025-00117-y","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:51:05Z","timestamp":1767113465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Translational investigation of tolinapant (ASTX660) in acute myeloid leukemia by integrating clinical, bioinformatic and pharmacological approaches"],"prefix":"10.1007","volume":"60","author":[{"given":"Keli","family":"Lima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederico Lisboa","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina Sofia Mateus","family":"Reis-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"de C\u00e1ssia Cavaglieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia Veras","family":"Costa-Lotufo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Agostinho","family":"Machado-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Magalh\u00e3es","family":"Rego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"117_CR1","doi-asserted-by":"publisher","first-page":"7314","DOI":"10.1021\/acs.jmedchem.8b00900","volume":"61","author":"CN Johnson","year":"2018","unstructured":"Johnson CN, Ahn JS, Buck IM, et al. A fragment-derived clinical candidate for antagonism of X-linked and cellular inhibitor of apoptosis proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660). J Med Chem. 2018;61:7314\u201329.","journal-title":"J Med Chem"},{"key":"117_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107610","volume":"214","author":"S Kumar","year":"2020","unstructured":"Kumar S, Fairmichael C, Longley DB, Turkington RC. The multiple roles of the IAP super-family in cancer. Pharmacol Ther. 2020;214:107610.","journal-title":"Pharmacol Ther"},{"key":"117_CR3","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1158\/1535-7163.MCT-17-0848","volume":"17","author":"GA Ward","year":"2018","unstructured":"Ward GA, Lewis EJ, Ahn JS, et al. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1\/2 and XIAP, Potently Induces TNFalpha-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth. Mol Cancer Ther. 2018;17:1381\u201391.","journal-title":"Mol Cancer Ther"},{"key":"117_CR4","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/bloodadvances.2020003955","volume":"5","author":"N Ferrari","year":"2021","unstructured":"Ferrari N, Ward G, Gewinner C, et al. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Adv. 2021;5:4003\u201316.","journal-title":"Blood Adv"},{"key":"117_CR5","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"117_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"117_CR7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526\u201331.","journal-title":"Nature"},{"issue":"850\u2013864","key":"117_CR8","first-page":"e859","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40(850\u2013864):e859.","journal-title":"Cancer Cell"},{"key":"117_CR9","doi-asserted-by":"crossref","unstructured":"Vinod Kumar K, Kumar A, Kundal K, et al. AMLdb: a comprehensive multi-omics platform to identify biomarkers and drug targets for acute myeloid leukemia. Brief Funct Genomics. 2024;23:798\u2013805.","DOI":"10.1093\/bfgp\/elae024"},{"key":"117_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41408-022-00747-w","volume":"12","author":"K Lima","year":"2022","unstructured":"Lima K, Pereira-Martins DA, de Miranda LBL, et al. The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy. Blood Cancer J. 2022;12:151.","journal-title":"Blood Cancer J"},{"key":"117_CR11","doi-asserted-by":"crossref","unstructured":"Lima K, Carvalho MFL, Pereira-Martins DA, et al. Pharmacological Inhibition of PIP4K2 Potentiates Venetoclax-Induced Apoptosis in Acute Myeloid Leukemia. Int J Mol Sci. 2023;24:16899.","DOI":"10.3390\/ijms242316899"},{"key":"117_CR12","doi-asserted-by":"crossref","unstructured":"Davids MS, Letai A. ABT-199: taking dead aim at BCL-2. Cancer Cell. 2013;23:139\u2013141.","DOI":"10.1016\/j.ccr.2013.01.018"},{"key":"117_CR13","doi-asserted-by":"publisher","first-page":"105207","DOI":"10.1016\/j.tiv.2021.105207","volume":"76","author":"CSM Reis-Silva","year":"2021","unstructured":"Reis-Silva CSM, Branco PC, Lima K, et al. Embelin potentiates venetoclax-induced apoptosis in acute myeloid leukemia cells. Toxicol In Vitro. 2021;76:105207.","journal-title":"Toxicol In Vitro"},{"key":"117_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-025-01346-1","volume":"15","author":"N Gangat","year":"2025","unstructured":"Gangat N, Dinardo CD. Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms. Blood Cancer J. 2025;15:139.","journal-title":"Blood Cancer J"},{"key":"117_CR15","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1080\/17474086.2024.2429604","volume":"17","author":"QZ Tatarata","year":"2024","unstructured":"Tatarata QZ, Wang Z, Konopleva M. Bcl-2 inhibition in acute myeloid leukemia: resistance and combinations. Expert Rev Hematol. 2024;17:935\u201346.","journal-title":"Expert Rev Hematol"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00117-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-025-00117-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00117-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:51:06Z","timestamp":1767113466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-025-00117-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["117"],"URL":"https:\/\/doi.org\/10.1007\/s44313-025-00117-y","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}